UniProt Q07820
Induced myeloid leukemia cell differentiation protein Mcl-1 (Q07820)
Induced myeloid leukemia cell differentiation protein Mcl-1 (UniProt Q07820): 157 experimental structures on GenesisL1, 61 ligands bound, 31 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- Q07820
- Protein
- Induced myeloid leukemia cell differentiation protein Mcl-1
- Experimental structures
- 157
- Predicted models
- 0
- Ligands
- 61
- Pockets
- 31 · 6 records with a druggable one
Structures
157 records of Q07820 in the MolNFT archive: 157 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 2KBW | Solution Structure of human Mcl-1 complexed with human Bid_BH3 peptide | solution nmr | A | — | — |
| 2KBW | Solution structure of human mcl-1 complexed with human BID_BH3 peptide | solution nmr | A | — | — |
| 2MHS | NMR Structure of human Mcl-1 | solution nmr | A | — | — |
| 2MHS | NMR structure of human mcl-1 | solution nmr | A | — | — |
| 2NL9 | Crystal structure of the Mcl-1:Bim BH3 complex | x-ray diffraction | A | — | — |
| 2NL9 | Crystal structure of the mcl-1:BIM BH3 complex | x-ray diffraction | A | — | — |
| 2NLA | Crystal structure of the Mcl-1:mNoxaB BH3 complex | x-ray diffraction | A | — | — |
| 2NLA | Crystal structure of the mcl-1:MNOXAB BH3 complex | x-ray diffraction | A | — | — |
| 2PQK | X-ray crystal structure of human Mcl-1 in complex with Bim BH3 | x-ray diffraction | A | — | — |
| 2PQK | X-ray crystal structure of human mcl-1 in complex with bim BH3 | x-ray diffraction | A | — | — |
| 3D7V | Crystal structure of Mcl-1 in complex with an Mcl-1 selective BH3 ligand | x-ray diffraction | A | — | — |
| 3D7V | Crystal structure of mcl-1 in complex with an mcl-1 selective BH3 ligand | x-ray diffraction | A | — | — |
| 3IO9 | BimL12Y in complex with Mcl-1 | x-ray diffraction | A | — | — |
| 3IO9 | BIML12Y in complex with mcl-1 | x-ray diffraction | A | — | — |
| 3KJ0 | Mcl-1 in complex with Bim BH3 mutant I2dY | x-ray diffraction | A | — | — |
| 3KJ0 | Mcl-1 in complex with bim BH3 mutant I2DY | x-ray diffraction | A | — | — |
| 3KJ1 | Mcl-1 in complex with Bim BH3 mutant I2dA | x-ray diffraction | A | — | — |
| 3KJ1 | Mcl-1 in complex with bim BH3 mutant I2DA | x-ray diffraction | A | — | — |
| 3KJ2 | Mcl-1 in complex with Bim BH3 mutant F4aE | x-ray diffraction | A | — | — |
| 3KJ2 | Mcl-1 in complex with bim BH3 mutant F4AE | x-ray diffraction | A | — | — |
| 3KZ0 | MCL-1 complex with MCL-1-specific selected peptide | x-ray diffraction | A, B | — | — |
| 3KZ0 | Mcl-1 complex with mcl-1-specific selected peptide | x-ray diffraction | A, B | — | — |
| 3MK8 | The MCL-1 BH3 Helix is an Exclusive MCL-1 Inhibitor and Apoptosis Sensitizer | x-ray diffraction | A, B | — | — |
| 3MK8 | The mcl-1 BH3 helix is an exclusive mcl-1 inhibitor and apoptosis sensitizer | x-ray diffraction | A, B | — | — |
| 3PK1 | Crystal structure of Mcl-1 in complex with the BaxBH3 domain | x-ray diffraction | A, C | — | — |
| 3PK1 | Crystal structure of mcl-1 in complex with the BAXBH3 domain | x-ray diffraction | A, C | — | — |
| 3TWU | Crystal structure of ARC4 from human Tankyrase 2 in complex with peptide from human MCL1 | x-ray diffraction | B | — | — |
| 3TWU | Crystal structure of ARC4 from human tankyrase 2 in complex with peptide from human MCL1 | x-ray diffraction | B | — | — |
| 3WIX | Crystal structure of Mcl-1 in complex with compound 4 | x-ray diffraction | A, B, C, D | — | — |
| 3WIX | Crystal structure of mcl-1 in complex with compound 4 | x-ray diffraction | A, B, C, D | — | — |
| 3WIY | Crystal structure of Mcl-1 in complex with compound 10 | x-ray diffraction | A, B, C, D, E, F | — | — |
| 3WIY | Crystal structure of mcl-1 in complex with compound 10 | x-ray diffraction | A, B, C, D, E, F | — | — |
| 4BPI | Mcl-1 bound to alpha beta Puma BH3 peptide 2 | x-ray diffraction | A | — | — |
| 4BPI | Mcl-1 bound to alpha beta puma BH3 peptide 2 | x-ray diffraction | A | — | — |
| 4BPJ | Mcl-1 bound to alpha beta Puma BH3 peptide 3 | x-ray diffraction | A | — | — |
| 4BPJ | Mcl-1 bound to alpha beta puma BH3 peptide 3 | x-ray diffraction | A | — | — |
| 4HW2 | Discovery of potent Mcl-1 inhibitors using fragment-based methods and structure-based design | x-ray diffraction | A, B, C, D, E, F | — | — |
| 4HW2 | Discovery of potent mcl-1 inhibitors using fragment-based methods and structure-based design | x-ray diffraction | A, B, C, D, E, F | — | — |
| 4HW3 | Discovery of potent Mcl-1 inhibitors using fragment-based methods and structure-based design | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | — | — |
| 4HW3 | Discovery of potent mcl-1 inhibitors using fragment-based methods and structure-based design | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | — | — |
| 4HW4 | Discovery of potent Mcl-1 inhibitors using fragment-based methods and structure-based design | x-ray diffraction | A, B | — | — |
| 4HW4 | Discovery of potent mcl-1 inhibitors using fragment-based methods and structure-based design | x-ray diffraction | A, B | — | — |
| 4OQ5 | Crystal Structure of Human MCL-1 Bound to Inhibitor… | x-ray diffraction | A, B, C, D, E, F | — | — |
| 4OQ5 | Crystal structure of human mcl-1 bound to inhibitor 4-(4… | x-ray diffraction | A, B, C, D, E, F | — | — |
| 4OQ6 | Crystal Structure of Human MCL-1 Bound to Inhibitor 4-hydroxy-4'-propylbiphenyl-3-carboxylic acid | x-ray diffraction | A, B | — | — |
| 4OQ6 | Crystal structure of human mcl-1 bound to inhibitor 4-hydroxy-4'- propylbiphenyl-3-carboxylic acid | x-ray diffraction | A, B | — | — |
| 4WGI | A Single Diastereomer of a Macrolactam Core Binds Specifically to Myeloid Cell Leukemia 1 (MCL1) | x-ray diffraction | A | — | — |
| 4WGI | A single diastereomer of a macrolactam core binds specifically to myeloid cell leukemia 1 (MCL1) | x-ray diffraction | A | — | — |
| 4WMR | STRUCTURE OF MCL1 BOUND TO BRD inhibitor ligand 1 AT 1.7A | x-ray diffraction | A | — | — |
| 4WMR | Structure of MCL1 bound to brd inhibitor ligand 1 at 1.7A | x-ray diffraction | A | — | — |
| 4WMS | Structure of apo mbp-MCL1 at 1.9A | x-ray diffraction | A | — | — |
| 4WMT | Structure of mbp-MCL1 bound to ligand 1 at 2.35A | x-ray diffraction | A | — | — |
| 4WMU | Structure of mbp-MCL1 bound to ligand 2 at 1.55A | x-ray diffraction | A | — | — |
| 4WMV | Structure of mbp-MCL1 bound to ligand 4 at 2.4A | x-ray diffraction | A | — | — |
| 4WMW | The structure of mbp-MCL1 bound to ligand 5 at 1.9A | x-ray diffraction | A | — | — |
| 4WMX | The structure of mbp-MCL1 bound to ligand 6 at 2.0A | x-ray diffraction | A | — | — |
| 4ZBF | Mcl-1 complexed with small molecules | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | — | — |
| 4ZBF | Mcl-1 complexed with small molecules | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | — | — |
| 4ZBI | Mcl-1 complexed with small molecules | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | — | — |
| 4ZBI | Mcl-1 complexed with small molecules | x-ray diffraction | A, B, C, D, E, F, G, H, I, J, K, L | — | — |
97 records more on the page itself.
Ligands
- GLC · alpha-D-glucopyranose · in 15 records
- ZN · Zinc ion · in 8 records
- CL · Chloride ion · in 6 records
- JLE · (2~{R})-2-[[6-ethyl-5-(1~{H}-indol-4-yl)thieno[2,3-d]pyrimidin-4-yl]amino]-3-phenyl-propanoic acid · in 5 records
- 7LT · (5~{R},13~{S},17~{S})-5-[[4-chloranyl-3-(2-phenylethyl)phenyl]methyl]-13-[(4-chlorophenyl) methyl]-8-methyl-1,4,8,12,16-pentazatricyclo[15.8.1.0^{20,25}]hexacosa-20(25),21, 23-triene-3,7,15,26-tetrone · in 2 records
- ACE · Acetyl group · in 2 records
- ECM · 7-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy) propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-3-carboxylic acid · in 2 records
- ECY · 3-({11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1, 4]diazepino[1,2-a]indol-2(3H)-yl}methyl)benzoic acid · in 2 records
- JL8 · (2~{R})-2-[5-(3-chloranyl-2-methyl-4-oxidanyl-phenyl)-6-ethyl-thieno[2,3-d]pyrimidin-4-yl]oxy-3-phenyl-propanoic acid · in 2 records
- JLB · (2~{R})-2-[6-ethyl-5-(1~{H}-indol-5-yl)thieno[2,3-d]pyrimidin-4-yl]oxypropanoic acid · in 2 records
- N0S · (4s,7ar,9ar,10s,11e,15r)-6'-chloro-10-hydroxy-15-methyl-3',4',7A,8,9,9A,10,13,14,15-decahydro-2'H,3H, 5H-spiro[1,19-(ethanediylidene)-16lambda~6~-cyclobuta[i][1,4]oxazepino[3,4-F][1,2, 7]thiadiazacyclohexadecine-4,1'-naphthalene]-16,16, 18(7H,17H)-trione · in 2 records
- NH2 · Amino group · in 2 records
- OJW · (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(5-fluoranylfuran-2-yl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[(2-methylpyrazol-3-yl)methoxy]phenyl]propanoic acid · in 2 records
- Q4D · (4s,7ar,9ar,10s,11e,18r)-6'-chloro-10-[2-(3,3-difluoroazetidin-1-yl)ethoxy]-N-(dimethylsulfamoyl)-18-hydroxy-15-methyl-16-oxo-3',4',7,7A,8,9,9A,10,13, 14,15,16,17,18-tetradecahydro-2'H,3H,5H-spiro[1,19-(ethanediylidene)cyclobuta[n][1,4]oxazepino[4,3-A][1, 8]diazacyclohexadecine-4,1'-naphthalene]-18-carboxamide · in 2 records
- Q4V · (4s,7ar,9ar,10s,11e,18r)-6'-chloro-10,18-dihydroxy-15-methyl-16-oxo-3',4',7,7A,8,9,9A,10,13,14,15,16,17,18-tetradecahydro-2'H,3H,5H-spiro[1,19-(ethanediylidene) cyclobuta[n][1,4]oxazepino[4,3-A][1, 8]diazacyclohexadecine-4,1'-naphthalene]-18-carboxylic acid · in 2 records
- Q4Y · (4S,11E,17R)-6'-chloro-17-hydroxy-14-methyl-15-oxo-3', 4',8,9,10,13,14,15,16,17-decahydro-2'H,3H,5H,7H-spiro[1,18-(ethanediylidene)[1,4]oxazepino[4,3-A][1, 8]diazacyclopentadecine-4,1'-naphthalene]-17-carboxylic acid · in 2 records
- U6N · (2~{R})-2-[[7-but-2-ynyl-5-(3-chloranyl-2-methyl-phenyl)-6-ethyl-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-3-phenyl-propanoic acid · in 2 records
- 5X3 · 5-[[6-chloranyl-3-[3-(4-chloranyl-3,5-dimethyl-phenoxy)propyl]-7-(3,5-dimethyl-1~{H}-pyrazol-4-yl)-1~{H}-indol-2-yl]carbonylsulfamoyl]furan-2-carboxylic acid · in 1 record
- 6AK · 4-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-6-carboxylic acid · in 1 record
- 6AL · 3-({6-chloro-3-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carbonyl}amino)benzoic acid · in 1 record
- 70R · (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(5-fluoranylfuran-2-yl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-[2,2,2-tris(fluoranyl)ethyl]pyrazol-3-yl]methoxy]phenyl]propanoic acid · in 1 record
- 7LW · (5~{R},13~{S},17~{S})-5-[(3,4-dichlorophenyl)methyl]-8-methyl-13-[(4-methylsulfonylphenyl)methyl]-1,4,8,12, 16-pentazatricyclo[15.8.1.0^{20,25}]hexacosa-20,22,24-triene-3,7,15,26-tetrone · in 1 record
- 9EA · 7-(3-{[4-(4-acetylpiperazin-1-yl)phenoxy]methyl}-1,5-dimethyl-1H-pyrazol-4-yl)-3-{3-[(naphthalen-1-yl) oxy]propyl}-1-[(pyridin-3-yl)methyl]-1H-indole-2-carboxylic acid · in 1 record
- ADM · Adamantane · in 1 record
- BNL · Biphenyl · in 1 record
- CJY · 3-{3-[(naphthalen-1-yl)oxy]propyl}-1H-indole-2-carboxylic acid · in 1 record
- CN7 · 7-(2-methylphenyl)-1-[2-(morpholin-4-yl)ethyl]-3-{3-[(naphthalen-1-yl)oxy]propyl}-1H-indole-2-carboxylic acid · in 1 record
- E4K · 7-(2-methylphenyl)-3-[3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl]-1~{H}-indole-2-carboxylic acid · in 1 record
- E4Q · 7-[3-[(1,5-dimethylpyrazol-3-yl)methylsulfanylmethyl]-1,5-dimethyl-pyrazol-4-yl]-3-(3-naphthalen-1-yloxypropyl)-1~{H}-indole-2-carboxylic acid · in 1 record
- E4W · Azd5991 · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.